Cargando…
In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.
The novel imidazoisoquinoline SDZ 62-434, originally identified as a platelet-activating factor (PAF) antagonist, has antiproliferative activity in a range of cell lines from human solid and haematological malignancies. Using an MTT cytotoxicity assay, IC50 values of 5 microM - 111 microM were obser...
Autores principales: | Brunton, V. G., Workman, P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968438/ https://www.ncbi.nlm.nih.gov/pubmed/8388233 |
Ejemplares similares
-
SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
por: Loor, F., et al.
Publicado: (1992) -
434. Neurocysticercosis in Houston
por: McKenna, Megan, et al.
Publicado: (2018) -
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997) -
Synthesis, Characterization and High In Vitro Antitumour Activity
of Novel Triphenyltin Carboxylates
por: Gielen, Marcel, et al.
Publicado: (1994) -
Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
por: Colombo, T., et al.
Publicado: (1996)